An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity
about
Evolutionary divergence and functions of the human interleukin (IL) gene familyInterferon lambda: a new sword in cancer immunotherapyA Mouse Model of Zika Virus PathogenesisAlpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infectionInterleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replicationInterferon-λ: Immune Functions at Barrier Surfaces and BeyondType I interferon blockade in systemic lupus erythematosus: where do we stand?Subversion of cytokine networks by virally encoded decoy receptorsIFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production.Leukocyte-derived IFN-α/β and epithelial IFN-λ constitute a compartmentalized mucosal defense system that restricts enteric virus infectionsInterferon- Is Functionally an Interferon but Structurally Related to the Interleukin-10 FamilyIFN-λ: A New Inducer of Local Immunity against Cancer and InfectionsInterferon-lambdas: the modulators of antivirus, antitumor, and immune responsesModulation of human plasmacytoid DC function by IFN-lambda1 (IL-29)Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokinesIFN-lambda determines the intestinal epithelial antiviral host defenseInterferons and their receptors in birds: a comparison of gene structure, phylogenetic analysis, and cross modulationLethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection.Postinfluenza bacterial pneumonia: host defenses gone awry.Transcriptional regulation of IFN-λ genes in hepatitis C virus-infected hepatocytes via IRF-3·IRF-7·NF-κB complexEx vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.Interferon induction and function at the mucosal surface.Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses.MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV.A novel high-throughput cell-based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug deliveryCharacterization of the bovine type I IFN locus: rearrangements, expansions, and novel subfamiliesThe alpha/beta interferon receptor provides protection against influenza virus replication but is dispensable for inflammatory response signaling.Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epitheliumExpression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs.Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infectionsType III IFN receptor expression and functional characterisation in the pteropid bat, Pteropus alecto.Interferon-λ in HCV Infection and Therapy.Genetic variation of the IL-28B promoter affecting gene expression.Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B.Prophylactic and therapeutic modulation of innate and adaptive immunity against mucosal infection of herpes simplex virusIFN-λ exerts opposing effects on T cell responses depending on the chronicity of the virus infection.Bovine type III interferon significantly delays and reduces the severity of foot-and-mouth disease in cattle.Morphine suppresses IFN signaling pathway and enhances AIDS virus infection.IFN-λ3 inhibits HIV infection of macrophages through the JAK-STAT pathway.IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population.
P2860
Q21245454-7606364A-D7EA-4486-9B47-C3F0B86245F9Q21296797-895DFC41-ED90-4DDF-8A2D-1BFA2D2C8B8CQ24261408-8F73B5BB-3DFE-42B6-A1F6-B0C9D5E678E4Q24611884-70E88DDD-23FF-4F83-BE5E-160420491947Q24651415-7A505999-D17A-4F0F-A230-38BA7FC3D336Q26801049-5D813260-BF93-4F73-B06B-B7231FFFCFC4Q26865441-D54EB7A2-DE97-44B3-8F79-D4D01D4FA131Q27005694-504D4897-9489-4556-B798-538978089F1FQ27308880-ACA524FA-9D1A-4D0C-9B6C-A07D4D598025Q27320523-EF03D0A5-4F4F-4309-A28A-616710BBDCEAQ27655546-1BCC64EF-B500-4512-AB75-10151B6EAEE7Q28072995-F9F965D9-2F44-478C-8D5C-5F39B1E76509Q28238963-F1005D86-7ED1-4A10-8246-061D6D101E8FQ28258808-7FEDE3A1-0568-441C-9612-7D63780F0C24Q28260203-7FBAA18B-44E4-488A-A3FE-7F6B8C830F88Q28508039-18A46388-4455-406A-B8D4-3E9D3610E847Q28649915-BC6E6387-CDF3-41A8-98F1-C2DB8C9DD540Q30389709-36B5775E-2857-417A-B09A-56D19062CFFDQ30392817-629524AD-9DA3-41E7-A4A4-017D0BBDA7A3Q30407935-D092F957-46C2-430B-BD65-3989260AC999Q30444198-92C8C319-106A-44E5-908D-4CB13CC0959EQ30661545-875C60D5-2BAE-4CAA-A594-3CFB8E493099Q33369068-771F1D74-EDB0-4EAE-83F2-D3E9FA0E3DB4Q33392688-08A7FADB-3E6E-4455-8F24-ABE4F40EAA13Q33425353-64439312-9D92-41B2-A971-7FD78B020640Q33434897-22C31779-46D5-4B17-8C3F-7A2EB4EEE859Q33614615-90785DC9-A1BD-40EA-8675-9708A5163411Q33747598-1DF7FD02-3FD7-480A-9137-DAB16E391881Q33826704-C0740C13-3168-4037-97D5-D607D87F89F7Q33877293-F310B4C7-A25D-4499-BA7B-01403D39483EQ34043150-F6DF72EF-B0F6-4203-A0E7-BCD338C0DF9BQ34047500-0D553E74-89F2-4FE5-8CEE-AA0778F27869Q34064550-8294D40C-570E-415B-B908-CDE01A0740EAQ34075388-6F0A4A2A-1974-4665-9589-0A64E2E98E8DQ34105712-632539A7-BC39-4EDC-99C0-438C81255CC4Q34147632-16007D5C-0F77-46A0-9C7E-72EEDF633969Q34149287-41B28740-A958-40D6-A1AE-D9D42DE918E4Q34168153-D9A12515-5752-4C20-A8AF-95BA1453D95EQ34256897-E9627CDC-7044-453E-99C5-C4455FC07989Q34287407-5D9205F6-A255-43D1-9F1D-BFC9651D5405
P2860
An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity
description
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2008
@ast
im Februar 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2008/02/15)
@sk
vědecký článek publikovaný v roce 2008
@cs
wetenschappelijk artikel (gepubliceerd op 2008/02/15)
@nl
наукова стаття, опублікована в лютому 2008
@uk
مقالة علمية (نشرت في 15-2-2008)
@ar
name
An important role for type III ...... TLR-induced antiviral activity
@ast
An important role for type III ...... TLR-induced antiviral activity
@en
An important role for type III ...... TLR-induced antiviral activity
@nl
type
label
An important role for type III ...... TLR-induced antiviral activity
@ast
An important role for type III ...... TLR-induced antiviral activity
@en
An important role for type III ...... TLR-induced antiviral activity
@nl
prefLabel
An important role for type III ...... TLR-induced antiviral activity
@ast
An important role for type III ...... TLR-induced antiviral activity
@en
An important role for type III ...... TLR-induced antiviral activity
@nl
P2093
P921
P3181
P1476
An important role for type III ...... TLR-induced antiviral activity
@en
P2093
Christina Bartholdy
Frederik Dagnaes-Hansen
Harald Haugen
Kevin Klucher
Marie B. Iversen
Peter Staeheli
Søren R. Paludan
Uffe B. Jensen
P304
P3181
P356
10.4049/JIMMUNOL.180.4.2474
P407
P577
2008-02-15T00:00:00Z